Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.

Aziz NazhaMikkael A SekeresRami KomrokjiDavid P SteensmaHagop KantarjianGail RobozPierre FenauxThomas PrebetNozar AzarniaPatrick S ZbyszewskiSteven M FruchtmanValeria SantiniLewis R SilvermanUwe PlatzbeckerGuillermo Garcia-Manero

Published in: Blood cancer journal (2017)

Keyphrases

phase iii
open label
clinical trial
phase ii
healthcare
double blind
palliative care
placebo controlled
quality improvement
pain management
affordable care act
randomized controlled trial
study protocol
health insurance